Transplant pharmacy: 30 Years of improving patient care

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1261-1263

  Burckart, Gilbert J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

BONE MARROW TRANSPLANTATION; DRUG BLOOD LEVEL; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; ORGAN TRANSPLANTATION; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACIST; PHARMACY; PRIORITY JOURNAL; SHORT SURVEY;

HUMANS; ORGAN TRANSPLANTATION; PATIENT CARE; PHARMACISTS; PHARMACY; TRANSPLANTS;

EID: 34547187583     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K239     Document Type: Short Survey

References (21)

1. Mitchell JF. Pharmacist involvement as a member of a renal transplant team. Am J Hosp Pharm 1976;33:55-8.
2. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107-32.
3. Venkataramanan R, Habucky K, Burckart GJ, et al. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989;16:134-61.
4. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
5. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al. Cyclosporine - high-dose steroid interaction in renal transplant recipients: assessment by HPLC. Transplant Proc 1987;19:1728-9.
6. D'Mello A, Venkataramanan R, Satake M, et al. Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Coram Chem Pathol Pharmacol 1989;64:441-54.
7. Steeves M, Abdallah HY, Venkataramanan R, et al. In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol 1991;43:574-7.
8. Wang CP, Burckart GJ, Ptachcinski RJ, et al. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc 1988;20:591-6.
9. Burckart GJ, Starzl TE, Venkataramanan R, et al. Excretion of cyclosporine and its metabolites in human bile. Transplant Proc 1986; 18:46-9.
10. Burckart GJ, Canafax DM, Yee GC. Cyclosporine monitoring. Drug Intell Clin Pharm 1986;20:649-52.
11. Ptachcinski RJ, Burckart GJ, Venkataramanan R, Ptachcinski RJ. Cyclosporine concentration determinations for monitoring and pharmacokinetic studies. J Clin Pharmacol 1986; 26:358-66.
12. Chisholm MA, Mulloy LL, DiPiro JT. Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. Clin Transplant 2005;19:77-82.
13. Chisholm MA, Mulloy LL, Jagadeesan M, et al. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant 2001;15:330-6.
14. Chisholm MA, Mulloy LL, Jagadeesan M, et al. Effect of clinical pharmacy services on the blood pressure of African-American renal transplant patients. Ethn Dis 2002;12:392-7.
15. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am J Health Syst Pharm 2005;62:1775-81.
16. Frampton JE, Faulds D. Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation. Pharmacoeconomics 1993;4:366-95.
17. Gault MH, Longerich LL, Vey EG, et al. Pharmacoeconomic comparison of cyclosporine oral solution and capsules after kidney transplantation. Nephron 1993;65:583-6.
18. Partovi N, Chan W, Nimmo CR. Evaluation of a patient education program for solid organ transplant patients. Can J Hosp Pharm 1995;48:72-8.
19. Ciminelli AM, Dupuis R, Williams D, et al. Patient education role of a pharmacist on a transplant service. Am J Health Syst Pharm 2000;57: 767-8.
20. Poveda Andrés JL, Font Noguera I, Monte Boquet E. Pharmacist's contribution to transplant patient care. Farm Hosp 2006;30:269-71.
21. Monnier G, Charpiat B, Serratrice F, et al. Evaluation of drug therapy knowledge in liver transplant patients after pharmacy counseling. Therapie 2003;58:305-11.